ПРЕПРИНТ
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
В настоящее время внимание исследователей приковано к изучению механизмов проникновения вируса SARS-Cov-2 в организм человека и последующего воздействия его на различные органы и системы. Тропность вируса к рецепторам ангиотензин-превращающего фермента 2 типа (АПФ2), которые находятся на поверхности различных клеток: пневмоцитов, эпителиоцитов пищевода и кишечника, кардиомиоцитов, эндотелия капилляров, мочевыделительной и нервной системы, а также в других органах, позволяет рассматривать возможность регулирования активности рецептора AПФ2 для лечения и профилактики инфекции COVID-19.
Омарова Х. Г., Макашова В. В., Понежева Ж. Б., Усенко Д. В., Малеев В. В., Акимкин В. Г. 2020. Некоторые аспекты патогенеза Сovid-19 и возможные патогенетические методы профилактики и лечения. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111737
1. Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens TS., Herrler G., Wu NH., Nitsche A., Muller MA., Drosten C., Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 doi: 10.1016/j.cell.2020.02.052.
2. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020 doi: 10.1016/j.cell.2020.02.058.
3. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454.
4. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828.
5. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond) 2020;134:543–545.
6. Kuba K, Imai Y, Penninger JM. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J. 2013;77:301–308.
7. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res. 2016;118:1313–1326.13.
8. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020 doi: 10.1007/s00134-020-05985-9.
9. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection [published online ahead of print, 2020 Apr 20]. Eur J Intern Med. 2020;76:14‐20. doi:10.1016/j.ejim.2020.04.037.
10. Bernstein KE, Khan Z, Giani JF, Cao DY, Bernstein EA, Shen XZ. Angiotensin-converting enzyme in innate and adaptive immunity. Nat Rev Nephrol. 2018;14:325–336.
11. Recinos A, 3rd, LeJeune WS, Sun H, Lee CY, Tieu BC, Lu M, Hou T, Boldogh I, Tilton RG, Brasier AR. Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis. 2007;194:125–133.
12. Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:2856–2864.
13. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–879.
14. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–116.
15. Hung YH, Hsieh WY, Hsieh JS, Liu FC, Tsai CH, Lu LC, Huang CY, Wu CL, Lin CS. Alternative Roles of STAT3 and MAPK Signaling Pathways in the MMPs Activation and Progression of Lung Injury Induced by Cigarette Smoke Exposure in ACE2 Knockout Mice. Int J Biol Sci. 2016;12:454–465.
16. Lin CI, Tsai CH, Sun YL, Hsieh WY, Lin YC, Chen CY, Lin CS. Instillation of particulate matter 2.5 induced acute lung injury and attenuated the injury recovery in ACE2 knockout mice. Int J Biol Sci. 2018;14:253–265.
17. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631–637.
18. Barkauskas CE, Cronce MJ, Rackley CR, Bowie EJ, Keene DR, Stripp BR, Randell SH, Noble PW, Hogan BL. Type 2 alveolar cells are stem cells in adult lung. J Clin Invest. 2013;123:3025–3036.
19. Rivellese F, Prediletto E. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102536:102536.
20. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A, Network C-LI. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 doi: 10.1001/jama.2020.5394.
21. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 doi: 10.1001/jamainternmed.2020.0994.
22. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 doi: 10.1016/j.ijid.2020.03.017.
23. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, Ephtimios IE, Kitai I, Mederski BD, Shadowitz SB, Gold WL, Hawryluck LA, Rea E, Chenkin JS, Cescon DW, Poutanen SM, Detsky AS. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801–2809.
24. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–847.
25. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7) Physiol Rev. 2018;98:505–553.
26. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection [published online ahead of print, 2020 Apr 20]. Eur J Intern Med. 2020;76:14‐20. doi:10.1016/j.ejim.2020.04.037.
27. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ, Janssens W, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson S Jr, Stelmach I, Kumar GT, Urashima M, Camargo CA Jr. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 356: i6583, 2017. doi:10.1136/bmj.i6583.
28. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D // Am J Physiol Renal Physiol. 2005. Vol. 289(1). P. 8–28.7].
29. Gouni-Berthold I., Krone W., Berthold H.K. Vitamin D and cardiovascular disease // Curr Vasc Pharmacol. 2009. Vol. 7(3). P. 414–422.
30. Pilz S., Kienreich K., Tomaschitz A. et al. Vitamin D and cardiovascular disease: update and outlook // Scand J Clin Lab Invest. 2012. Suppl. 243. P. 83–91.
31. Kong J., Qiao G., Zhang Z. et al. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium // Kidney International. 2008. Vol. 74(12). P. 1577–1581. doi: 10.1038/ki.2008.452.
32. Müller K., Haahr P.M., Diamant M. et al. 1,25-dihydroxyVitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level // Cytokine. 1992. Vol. 4(6). P. 506–512.
33. Zittermann A., Schleithoff S.S., Tenderich G. et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? // J Am Coll Cardiol. 2003. Vol. 41(1). Р. 105–112.
34. Talmor Y., Golan E., Benchetrit S. et al. Calcitriol blunts the deleterious impact of advanced glycation and products on endothelial cells // Am J Physiol Renal Physiol. 2008. Vol. 294(5). P. 1059–1064.
35. Li C., Qiao G., Uskokovic M. et al. Vitamin D: a negative endocrine regulator of the reninangiotensin system and blood pressure // J Steroid Biochem Mol Biol. 2004. Vol. 89–90 (1–5). P. 387–392.
36. Hong M, Xiong T, Huang J, Wu Y, Lin L, Zhang Z, Huang L, Gao D, Wang H, Kang C, Gao Q, Yang X, Yang N, Hao L. Association of vitamin D supplementation with respiratory tract infection in infants. Matern Child Nutr 5: e12987, 2020. doi:10.1111/mcn.12987.
37. 37. Tsujino I, Ushikoshi-Nakayama R, Yamazaki T, Matsumoto N, Saito I. Pulmonary activation of vitamin D3 and preventive effect against interstitial pneumonia. J Clin Biochem Nutr 65: 245–251, 2019. doi:10.3164/jcbn.19-48. .
38. Zhou YF, Luo BA, Qin LL. The association between vitamin D deficiency and community-acquired pneumonia: A meta-analysis of observational studies. Medicine (Baltimore) 98: e17252, 2019. doi:10.1097/MD.0000000000017252.
39. Huang F, Zhang C, Liu Q, Zhao Y, Zhang Y, Qin Y, Li X, Li C, Zhou C, Jin N, Jiang C. Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury. PLoS Pathog 16: e1008341, 2020. doi:10.1371/journal.ppat.1008341.
40. Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol Med Rep 16: 7432–7438, 2017. doi:10.3892/mmr.2017.7546.).
41. Jolliffe DA, Greiller CL, Mein CA, Hoti M, Bakhsoliani E, Telcian AG, Simpson A, Barnes NC, Curtin JA, Custovic A, Johnston SL, Griffiths CJ, Walton RT, Martineau AR. Vitamin D receptor genotype influences risk of upper respiratory infection. Br J Nutr 120: 891–900, 2018. doi:10.1017/S000711451800209X.
42. Kwak JH, Paik JK. Reply to Jakovac: “COVID-19 and vitamin D—Is there a link and an opportunity for intervention?”. Am J Physiol Endocrinol Metab. 2020;319(1):E1. doi:10.1152/ajpendo.00197.2020.
43. Uwitonze AM, Razzaque MS. Role of magnesium in Vitamin D activation and function. J Am Osteopath Assoc 118: 181–189, 2018. doi:10.7556/jaoa.2018.037.
44. Cantorna MT, Snyder L, Arora J. Vitamin A and vitamin D regulate the microbial complexity, barrier function, and the mucosal immune responses to ensure intestinal homeostasis. Crit Rev Biochem Mol Biol 54: 184–192, 2019. doi:10.1080/10409238.2019.1611734.
45. Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, Peng Z, Pan H. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol 127: 104364, 2020. doi:10.1016/j.jcv.2020.104364.
46. Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord 18: 153–165, 2017. doi:10.1007/s11154-017-9424-1.
47. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that Vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 12: E988, 2020. doi:10.3390/nu12040988.
48. Vasarhelyi B., Satori A., Olajos F., Szabo A., Beko G. Low vitamin D levels among patients at Semmelweis University: Retrospective analysis during a one-year period. Orv. Hetil. 2011;152:1272–1277. doi: 10.1556/OH.2011.29187.
49. Novel C.P.E.R.E. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145–151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003.
50. Grober U., Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol. 2012;4:158–166. doi: 10.4161/derm.20731.
51. Jakovac H. COVID-19 and vitamin D—Is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab 318: E589, 2020. doi:10.1152/ajpendo.00138.2020.
52. Дупланчич Д., Цезарич М., Поляк Н.К. и др. Влияние селективного активатора рецептора витамина D парикальцитола на сердечно-сосудистую систему и кардио-ренальную протекцию // Нефрология. 2014. T. 18(2). С. 25–32 [Duplanchich D., Tsezarich M., Polyak N.K. i dr. Vliyaniye selektivnogo aktivatora retseptora vitamina D parikal’tsitola na serdechno-sosudistuyu sistemu i kardiorenal’nuyu protektsiyu // Nefrologiya. 2014. T. 18(2). S. 25–32 (in Russian)].
53. Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease // Drugs. 2007. Vol. 67. P. 1999–2012.
54. Annweiler C, Cao Z, Wu Y, et al. Counter-regulatory 'Renin-Angiotensin' System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected patients [published online ahead of print, 2020 May 17. Infect Disord Drug Targets. 2020;10.2174/1871526520666200518073329. doi:10.2174/1871526520666200518073329].
55. Facchiano A, Facchiano A, Bartoli M, Ricci A, Facchiano F. Reply to Jakovac: About COVID-19 and vitamin D. Am J Physiol Endocrinol Metab. 2020;318(6):E838. doi:10.1152/ajpendo.00185.2020.
